Life Sciences

  • April 28, 2026

    Ex-Fauci Adviser Charged With Concealing COVID Records

    Federal prosecutors have charged a former adviser to Dr. Anthony Fauci with deleting government emails and using his personal email account to dodge public records requests about the origins of the COVID-19 virus.

  • April 28, 2026

    Purdue Pharma's $5.5B Plea Deal Clinched As Survivors Protest

    OxyContin maker Purdue Pharma LP has to pay a $3.5 billion fine and forfeit an additional $2 billion, more than five years after it pled guilty to criminal charges related to its role in the opioid crisis, a New Jersey federal judge said Tuesday.

  • April 28, 2026

    MedMal Case Volume Declines, But Doctor Risks Remain High

    While the volume of malpractice lawsuits against U.S. physicians has dropped in recent years, that doesn't mean the threat of legal liability is dissipating, according to a report released Monday by the American Medical Association. 

  • April 28, 2026

    Paul Hastings, Gibson Dunn Steer $739M Ligand-Xoma Deal

    Ligand Pharmaceuticals said it plans to purchase XOMA Royalty in a $739 million deal combining the two biotechnology royalty aggregator companies advised by Gibson Dunn & Crutcher LLP and Paul Hastings LLP.

  • April 28, 2026

    Walgreens Can't Use Recording To Undo Investor Claim In Ill.

    An Illinois federal judge has said she won't toss a claim brought by shareholders alleging a former Walgreens president made a false and misleading statement during an investor conference, rejecting the company's argument that an audio recording of that conference warranted a second look at her dismissal ruling.

  • April 28, 2026

    Chinese Man Extradited From Italy Over COVID Data Theft

    A Chinese citizen has appeared before a Houston federal court after being extradited from Italy to face charges for his alleged role in the Microsoft "HAFNIUM" cyberattack that was allegedly orchestrated by the Chinese government to target U.S. COVID-19 research.

  • April 28, 2026

    Hikma, Cipla Cut Deals In Pfizer Heart Drug Patent Case

    Hikma Pharmaceuticals PLC and Cipla Ltd. have reached settlements with Pfizer Inc. in a case over the two defendants' efforts to create generic versions of the heart medication Vyndamax.

  • April 28, 2026

    Maryland Justices Allow IVF Cost Class Action To Proceed

    A Maryland couple can pursue a proposed class action against a health insurer that they say wrongfully denied coverage for embryo thawing in connection with an in vitro fertilization procedure, the Maryland Supreme Court has ruled, finding that the insurer's subsequent payment of the claim doesn't moot the suit.

  • April 28, 2026

    Eli Lilly Inks $2.25B AI Genetics Research Pact With Profluent

    AI-focused biotech Profluent said Tuesday it has entered a multiprogram, strategic research collaboration with Eli Lilly and Co. to treat diseases with high unmet need, in a deal that involves an upfront payment and up to $2.25 billion in additional milestone payments. 

  • April 28, 2026

    Meet The Attys Arguing The High Court 'Skinny Label' Case

    When the U.S. Supreme Court hears arguments Wednesday in a patent case involving "skinny labels" on generic drugs, a longtime patent attorney as well as a government attorney who often handles intellectual property cases will face an appellate specialist who has argued many high court cases.

  • April 27, 2026

    North Dakota Drug-Pricing Law Blocked In Pharma Fight

    A North Dakota federal judge on Monday blocked the state's new drug-pricing law, agreeing with pharmaceutical companies that while the law purports to "protect the underdogs," it illegally interferes with the federal drug-pricing regime.

  • April 27, 2026

    Did Hedge Fund 'Greed' Hurt Vaxart Investors? Jury To Decide

    Armistice Capital and two of its executives used misleading press releases to pump and dump $250 million in Vaxart stock during the pandemic through misleading press releases in an act of pandemic-era "greed," investors' counsel told a California federal jury during closing arguments Monday, while the hedge fund defendants' lawyer countered Vaxart's announcements were "true and accurate."

  • April 27, 2026

    DOJ Says Wash. 340B Drug Law Is Preempted In Novartis Suit

    The U.S. Department of Justice waded into a dispute between pharmaceutical giants and the state of Washington on Monday, arguing that federal law preempts a new state law that expands discounts that drugmakers must provide under the federal 340B Drug Pricing Program.

  • April 27, 2026

    High Court Appears Split In Monsanto Roundup Appeal

    Monsanto's efforts to stem the tide of thousands of lawsuits over its blockbuster weedkiller Roundup seemed to find a mixed audience with the U.S. Supreme Court justices Monday as they debated the benefits of national labeling standards with how regulators stay on top of changing science.

  • April 27, 2026

    Moderna Hit With Suit Over CureVac COVID Patents

    BioNTech subsidiary CureVac has launched a new patent infringement suit against Moderna, claiming its COVID-19 vaccine infringed a handful of patents, saying the Massachusetts-based company "exploited" its messenger RNA technology.

  • April 27, 2026

    Attys, Advocates Call DOJ Pot Rule Historic Shift For Feds

    Legal strategies are evolving quickly in the wake of last week's "historic" rescheduling of state-legal medical cannabis, as a group of attorneys and advocates gathered Monday to evaluate the trade-offs of dispensaries now being able to register like pharmacies with the feds and the potential effect on industry investments and trade.

  • April 27, 2026

    IQVIA Accuses Ex-Execs, Syneos Of Poaching $180M Client

    IQVIA Holdings Inc. is accusing former executives of defecting to a competitor in the clinical research organization industry and initiating a corporate raid that resulted in the loss of one customer worth at least $180 million, according to a lawsuit filed in North Carolina Business Court.

  • April 27, 2026

    4 Firms Build Astorg's $1.1B Microbiology Biz Buy

    Life sciences company Thermo Fisher Scientific Inc. on Monday announced plans to sell its microbiology business to European private equity firm Astorg in an over $1.1 billion deal steered by four law firms.

  • April 27, 2026

    3rd Circ. Panel Once Again Backs Talc Co. Whittaker's Ch. 11

    The Third Circuit on Monday upheld its decision that Whittaker Clark & Daniels was authorized to file for Chapter 11 and certain claims against the defunct talc supplier's corporate successor belong to the debtor, not personal injury claimants.

  • April 27, 2026

    Bioscience Co. Allegedly Hid Volatility Risks From Investors

    A company purportedly focused on using traditional Chinese medicine to treat conditions including autism spectrum disorder faces a proposed investor class action alleging it downplayed the risk it would be probed in connection with unusual volatility affecting the market for its shares.

  • April 27, 2026

    McCarter & English Plans New Waterfront Home In Boston

    New Jersey-based McCarter & English LLP has chosen a new home for its Boston office, opting for a location in the middle of the city's downtown waterfront district, the firm has announced.

  • April 27, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week tackled a fresh mix of deal litigation, procedural disputes and fiduciary duty claims, with several rulings and filings underscoring the court's continued focus on contractual precision, forum enforcement and the limits of stockholder challenges.

  • April 27, 2026

    What To Watch As Justices Take On 'Skinny Label' Case

    The U.S. Supreme Court will hear arguments Wednesday on whether to permit a patent suit over a generic heart drug using a so-called skinny label, a case with ramifications for the drug industry that could shape patent disputes more broadly and other legal areas. Here's what to watch for.

  • April 27, 2026

    Ropes & Gray, Cooley Lead Lilly's $2.3B Cancer Drug Buy

    Eli Lilly and Co. said Monday it will acquire privately held Ajax Therapeutics in a deal worth up to $2.3 billion, as the drugmaker looks to expand its pipeline of treatments for blood cancers.

  • April 27, 2026

    US, Indian Firms Guide $11.75B Sun Pharma-Organon Deal

    Indian pharmaceutical giant Sun Pharmaceutical Industries Ltd. has agreed to acquire New Jersey-based Organon & Co. in an all-cash deal valued at $11.75 billion, with each side of the transaction having representation from one U.S. and one Indian law firm.

Expert Analysis

  • Series

    Preaching Makes Me A Better Lawyer

    Author Photo

    Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.

  • A Look At Middlemen Fees In 340B Drug Discount Program

    Author Photo

    A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.

  • How Large Patent Damages Awards Actually Play Out

    Author Photo

    Most large verdicts in patent infringement cases are often overturned or reduced on appeal, implying that the Federal Circuit is serving its intended purpose of correcting outlier outcomes, and that the figures that catch headlines and dominate policy debates may misrepresent economic realities, says Bowman Heiden at Berkeley School of Law.

  • Series

    Law School's Missed Lessons: Practicing Client-Led Litigation

    Author Photo

    New litigators can better help their corporate clients achieve their overall objectives when they move beyond simply fighting for legal victory to a client-led approach that resolves the legal dispute while balancing the company's competing out-of-court priorities, says Chelsea Ireland at Cohen Ziffer.

  • Navigating 2025's Post-Grant Proceeding Shakeups

    Author Photo

    Extensive changes to the U.S. Patent Trial and Appeal Board's post-grant proceedings this year, including the new settled expectations factor and revitalization of Fintiv factors, require petitioners and patent owners alike to be mindful when selecting patents to assert and challenge, say attorneys at Quinn Emanuel.

  • Series

    The Law Firm Merger Diaries: How To Build On Cultural Fit

    Author Photo

    Law firm mergers should start with people, then move to strategy: A two-level screening that puts finding a cultural fit at the pinnacle of the process can unearth shared values that are instrumental to deciding to move forward with a combination, says Matthew Madsen at Harrison.

  • Latisse Ruling's Lessons On Avoiding Chemical Patent Pitfalls

    Author Photo

    The Federal Circuit's decision in Duke v. Sandoz, reversing a $39 million infringement claim for selling a generic Latisse product, reinforces a fundamental truth in chemical patent strategy: Broad genus claims rarely survive without clear evidence of possession of specific embodiments, says Kimberly Vines at Stites & Harbison.

  • Considerations When Invoking The Common-Interest Privilege

    Author Photo

    To successfully leverage the common-interest doctrine in a multiparty transaction or complex litigation, practitioners should be able to demonstrate that the parties intended for it to apply, that an underlying privilege like attorney-client has attached, and guard against disclosures that could waive privilege and defeat its purpose, say attorneys at DLA Piper.

  • Series

    The Law Firm Merger Diaries: Making The Case To Combine

    Author Photo

    When making the decision to merge, law firm leaders must factor in strategic alignment, cultural compatibility and leadership commitment in order to build a compelling case for combining firms to achieve shared goals and long-term success, says Kevin McLaughlin at UB Greensfelder.

  • Key Risks For Cos. As MAHA Influences Food Regulation

    Author Photo

    As the Make America Healthy Again movement alters state and federal legislative and regulatory priorities, measures targeting ultra-processed foods, front-of-package labeling requirements and restrictions on schools are creating new compliance and litigation risks for food and beverage manufacturers, pharmaceutical companies, retailers and digital advertisers, say attorneys at Kelley Drye.

  • State AGs May Extend Their Reach To Nat'l Security Concerns

    Author Photo

    Companies with foreign supply-chain risk exposure need a comprehensive risk-management strategy to address a growing trend in which state attorneys general use broadly written state laws to target conduct that may not violate federal regulations, but arguably constitutes a national security threat, say attorneys at Wiley.

  • Opinion

    Despite Deputy AG Remarks, DOJ Can't Sideline DC Bar

    Author Photo

    Deputy Attorney General Todd Blanche’s recent suggestion that the D.C. Bar would be prevented from reviewing misconduct complaints about U.S. Department of Justice attorneys runs contrary to federal statutes, local rules and decades of case law, and sends the troubling message that federal prosecutors are subject to different rules, say attorneys at HWG.

  • Key Strategies For Supplement Cos. Facing Lead Risks

    Author Photo

    In the wake of a recent Consumer Reports article detailing dangerously high levels of lead in many popular protein powders, supplement companies face increased litigation, rising enforcement risks and reputational harm — underscoring the need to monitor supply chains, test ingredients and understand labeling standards, say attorneys at Husch Blackwell.

  • From Bank Loans To Private Credit: Tips For Making The Shift

    Author Photo

    The relationship between private credit and syndicated bank deals will evolve as the private market continues to grow, introducing new challenges for borrowers comparing financing options, particularly pertaining to loan documentation and working capital, say attorneys at Haynes Boone.

  • 3 Takeaways From FDA Cell And Gene Therapy Draft Guidance

    Author Photo

    The U.S. Food and Drug Administration recently published draft guidance documents that sketch the clearest picture yet of the evolving regulatory framework for cell and gene therapies, reflecting an agency that is increasingly comfortable with flexible, science-driven approaches that extend beyond clinical trial models, say attorneys at MoFo.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.